Abstract
Introduction
Glioblastoma (GBM) is an incurable cancer type. New therapeutic options are investigated, including targeting the mitogen-activated protein kinase (MAPK) pathway using MEK inhibitors as radio-sensitizers. In this study, we investigated whether MEK inhibition via PD0325901 leads to radio-sensitization in experimental in vitro and in vivo models of GBM.
Materials and Methods
In vitro, GBM8 multicellular spheroids were irradiated with 3 fractions of 2 Gy, during 5 consecutive days of incubation with either PD0325901 or MEK-162. In vivo, we combined PD0325901 with radiotherapy in the GBM8 orthotopic mouse model, tumor growth was measured weekly by bioluminescence imaging and overall survival and toxicity were assessed.
Results
Regrowth and viability of spheroids monitored until day 18, showed that both MEK inhibitors had an in vitro radio-sensitizing effect. In vivo, PD0325901 concentrations were relatively constant throughout multiple brain areas and temporal PD0325901-related adverse events such as dermatitis were observed in 4 out of 14 mice (29%). Mice that were treated with radiation alone or combined with PD0325901 had significantly better survival compared to vehicle (both P < 0.005), however, no significant interaction between PD0325901 MEK inhibition and irradiation was observed.
Conclusion
The difference between the radiotherapy-enhancing effect of PD0325901 in vitro and in vivo urges further pharmacodynamic/pharmacokinetic investigation of PD0325901 and possibly other candidate MEK inhibitors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All data is available on request.
References
Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM (2009) Age-incidence patterns of primary CNS tumors in children, adolescents, and adults in England. Neuro Oncol 11(4):403–413
Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ et al (2013) Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. Cancer Res 73(22):6745–6756
Brahm CG, Abdul UK, Houweling M, van Linde ME, Lagerweij T, Verheul HMW et al (2020) Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma. Neurooncol Adv. 2(1):151
Catalanotti F, Solit DB, Pulitzer MP, Berger MF, Scott SN, Iyriboz T et al (2013) Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma. Clin Cancer Res 19(8):2257–2264
Caunt CJ, Sale MJ, Smith PD, Cook SJ (2015) MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer 15(10):577–592
Chung EJ, Brown AP, Asano H, Mandler M, Burgan WE, Carter D et al (2009) In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res 15(9):3050–3057
Chung EJ, Urick ME, Kurshan N, Shield W 3rd, Asano H, Smith PD et al (2013) MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands. Int J Oncol 42(6):2028–2036
de Gooijer MC, Zhang P, Weijer R, Buil LCM, Beijnen JH, van Tellingen O (2018) The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors. Int J Cancer 142(2):381–391
DiResta GR, Lee JB, Arbit E (1991) Measurement of brain tissue specific gravity using pycnometry. J Neurosci Methods 39(3):245–251
Essien EI, Hofer TP, Atkinson MJ, Anastasov N (2022) Combining HDAC and MEK Inhibitors with radiation against glioblastoma-derived spheres. Cells 11(5):225
Gousias K, Markou M, Voulgaris S, Goussia A, Voulgari P, Bai M et al (2009) Descriptive epidemiology of cerebral gliomas in northwest Greece and study of potential predisposing factors, 2005–2007. Neuroepidemiology 33(2):89–95
Honeywell R, Yarzadah K, Giovannetti E, Losekoot N, Smit EF, Walraven M et al (2010) Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878(15–16):1059–1068
Hou J, Diao Y, Li W, Yang Z, Zhang L, Chen Z et al (2016) RGD peptide conjugation results in enhanced antitumor activity of PD0325901 against glioblastoma by both tumor-targeting delivery and combination therapy. Int J Pharm 505(1–2):329–340
Khosla D (2016) Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Ann Transl Med 4(3):54
Kim SY, Jeong EH, Lee TG, Kim HR, Kim CH (2021) The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor. Radiosens Lung Cancer Cell Antican Res 41(6):2885–2894
Korja M, Raj R, Seppä K, Luostarinen T, Malila N, Seppälä M et al (2019) Glioblastoma survival is improving despite increasing incidence rates: a nationwide study between 2000 and 2013 in Finland. Neuro Oncol 21(3):370–379
Lagerweij T, Sewing C, van Battum L, Koken P, Heukelom S (2021) Inhalation anesthesia and shielding devices to allow accurate preclinical irradiation of mice with clinical linac-based systems: design and dosimetric characteristics. Clin Transl Radiat Oncol 26:92–97
Lee CH, Jung KW, Yoo H, Park S, Lee SH (2010) Epidemiology of primary brain and central nervous system tumors in Korea. J Korean Neurosurg Soc 48(2):145–152
Lin SH, Zhang J, Giri U, Stephan C, Sobieski M, Zhong L et al (2014) A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer. J Thorac Oncol 9(7):965–973
Lu VM, Jue TR, McDonald KL (2020) Cytotoxic lanthanum oxide nanoparticles sensitize glioblastoma cells to radiation therapy and temozolomide: an in vitro rationale for translational studies. Sci Rep 10(1):18156
Narayan RS, Gasol A, Slangen PLG, Cornelissen FMG, Lagerweij T, Veldman H et al (2018) Identification of MEK162 as a radiosensitizer for the treatment of glioblastoma. Mol Cancer Ther 17(2):347–354
Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y et al (2013) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the united states in 2006–2010. Neuro Oncol 15(2):1–56
Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS (2020) CBTRUS statistical report primary brain and other central nervous system tumors diagnosed in the united states in 2013–2017. Neuro Oncol 22(12):1-i96
Perreault S, Larouche V, Tabori U, Hawkin C, Lippé S, Ellezam B et al (2019) A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01. BMC Cancer 19(1):1250
Philips A, Henshaw DL, Lamburn G, O’Carroll MJ (2018) Brain Tumours: Rise in Glioblastoma Multiforme incidence in england 1995–2015 suggests an adverse environmental or lifestyle factor. J Environ Public Health 2018:7910754
Praxinos GFK (2008) The mouse brain in stereotaxic coordinates. Compact, 3rd edn pp 1–136
Studebaker A, Bondra K, Seum S, Shen C, Phelps DA, Chronowski C et al (2015) Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Pediatr Blood Cancer 62(10):1768–1774
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466
Tran B, Cohen MS (2020) The discovery and development of binimetinib for the treatment of melanoma. Expert Opin Drug Discov 15(7):745–754
Voon PJ, Chen EX, Chen HX, Lockhart AC, Sahebjam S, Kelly K et al (2022) Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction. J Exp Clin Cancer Res 41(1):51
Yan Y, Black CP, Cowan KH (2007) Irradiation-induced G2/M checkpoint response requires ERK1/2 activation. Oncogene 26(32):4689–4698
Zhao Y, Adjei AA (2014) The clinical development of MEK inhibitors. Nat Rev Clin Oncol 11(7):385–400
Funding
This project was supported by the Dutch Cancer Society grant KWF-11038, Brain Tumour Charity Grant 488097 and the Amsterdam Innovation Exchange grant APCA-PoC-2017.
Author information
Authors and Affiliations
Contributions
BAW and PS conceptualized the work. MH, UKA, CB ad TL performed all laboratory and animal experiments, SH and PWK enabled the in vivo radiotherapy experiments, RH performed the pharmacokinetic study, LEW, GJP, HV, PS, DN, TW and BAW provided funding and supervision of the project.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no potential conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Houweling, M., Abdul, U.K., Brahm, C. et al. Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo. J Cancer Res Clin Oncol 149, 297–305 (2023). https://doi.org/10.1007/s00432-022-04483-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-022-04483-3